These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

420 related articles for article (PubMed ID: 33946905)

  • 1. Aminoglycosides in the Intensive Care Unit: What Is New in Population PK Modeling?
    Duong A; Simard C; Wang YL; Williamson D; Marsot A
    Antibiotics (Basel); 2021 Apr; 10(5):. PubMed ID: 33946905
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Amikacin in Critically Ill Patients: A Review of Population Pharmacokinetic Studies.
    Marsot A; Guilhaumou R; Riff C; Blin O
    Clin Pharmacokinet; 2017 Feb; 56(2):127-138. PubMed ID: 27324191
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Aminoglycoside Dosing and Volume of Distribution in Critically Ill Surgery Patients.
    Grucz TM; Kruer RM; Bernice F; Lipsett PA; Dorman T; Sugrue D; Jarrell AS
    Surg Infect (Larchmt); 2020 Dec; 21(10):859-864. PubMed ID: 32302517
    [No Abstract]   [Full Text] [Related]  

  • 4. Experience with a once-daily dosing program of aminoglycosides in critically ill patients.
    Buijk SE; Mouton JW; Gyssens IC; Verbrugh HA; Bruining HA
    Intensive Care Med; 2002 Jul; 28(7):936-42. PubMed ID: 12122533
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An Evaluation of Gentamicin, Tobramycin, and Amikacin Pharmacokinetic/Pharmacodynamic Parameters in HIV-Infected Children.
    Rodriguez JC; Schoenike S; Scott GB; Rossique-Gonzalez MT; Gomez-Marin O
    J Pediatr Pharmacol Ther; 2003 Oct; 8(4):274-83. PubMed ID: 23118683
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Exploring the Relationship between FEV
    Hoff BM; Scheetz MH; Jain M; Cullina JF; Rhodes NJ
    Pharmacotherapy; 2020 Jun; 40(6):584-591. PubMed ID: 32259317
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetic changes and dosing modification of aminoglycosides in critically ill obese patients: a literature review.
    Velissaris D; Karamouzos V; Marangos M; Pierrakos C; Karanikolas M
    J Clin Med Res; 2014 Aug; 6(4):227-33. PubMed ID: 24883145
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Aminoglycosides' dosing and monitoring practices in critically ill patients in Quebec hospitals.
    Duong A; Thirion DJG; Williamson D; Simard C; Marsot A
    J Chemother; 2022 Sep; 34(5):341-344. PubMed ID: 35238282
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Extended-interval aminoglycoside administration for children: a meta-analysis.
    Contopoulos-Ioannidis DG; Giotis ND; Baliatsa DV; Ioannidis JP
    Pediatrics; 2004 Jul; 114(1):e111-8. PubMed ID: 15231982
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Surveillance of aminoglycoside resistance. European data.
    Van Landuyt HW; Boelaert J; Glibert B; Gordts B; Verbruggen AM
    Am J Med; 1986 Jun; 80(6B):76-81. PubMed ID: 3089007
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Population Pharmacokinetic Study of the Suitability of Standard Dosing Regimens of Amikacin in Critically Ill Patients with Open-Abdomen and Negative-Pressure Wound Therapy.
    Carrié C; Delzor F; Roure S; Dubuisson V; Petit L; Molimard M; Breilh D; Biais M
    Antimicrob Agents Chemother; 2020 Mar; 64(4):. PubMed ID: 31964795
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Population pharmacokinetics of aminoglycosides in critically ill trauma patients on once-daily regimens.
    Barletta JF; Johnson SB; Nix DE; Nix LC; Erstad BL
    J Trauma; 2000 Nov; 49(5):869-72. PubMed ID: 11086778
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aminoglycoside pharmacokinetics in African-Americans with normal renal function.
    Oparaoji EC; Siram S; Elemihe U; Mezghebe HM; Cho T; Bashiri M; Piedrahita K; Pipalla RS
    J Clin Pharm Ther; 1998 Jun; 23(3):191-7. PubMed ID: 9831970
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Aminoglycoside dosing considerations in intensive care unit patients.
    Watling SM; Dasta JF
    Ann Pharmacother; 1993 Mar; 27(3):351-7. PubMed ID: 8267695
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relationship between hemodynamic and vital support measures and pharmacokinetic variability of amikacin in critically ill patients with sepsis.
    Lugo G; Castañeda-Hernández G
    Crit Care Med; 1997 May; 25(5):806-11. PubMed ID: 9187600
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Optimization of anti-pseudomonal antibiotics for cystic fibrosis pulmonary exacerbations: V. Aminoglycosides.
    Young DC; Zobell JT; Stockmann C; Waters CD; Ampofo K; Sherwin CM; Spigarelli MG
    Pediatr Pulmonol; 2013 Nov; 48(11):1047-61. PubMed ID: 24000183
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risk Factors Associated with Suboptimal Tobramycin Levels in the Medical Intensive Care Unit.
    Counts JP; Elefritz JL; Reed EE; Palettas M; Aossey C; Beatty JJ
    Eur J Drug Metab Pharmacokinet; 2022 Mar; 47(2):271-278. PubMed ID: 35029839
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Sensitivity of 1041 strains of bacteria obtained from an intensive care unit with regard to aminoglycosides].
    Beney E; Robert D; Tigaud S; Blanc PL; Vincent P
    Nouv Presse Med; 1982 Nov; 11(46):3396-9. PubMed ID: 7155847
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Aminoglycosides against carbapenem-resistant Enterobacteriaceae in the critically ill: the pitfalls of aminoglycoside susceptibility.
    Zavascki AP; Klee BO; Bulitta JB
    Expert Rev Anti Infect Ther; 2017 Jun; 15(6):519-526. PubMed ID: 28375030
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Population Pharmacokinetics of Amikacin Administered Once Daily in Patients with Different Renal Functions.
    Aréchiga-Alvarado NA; Medellín-Garibay SE; Milán-Segovia RDC; Ortiz-Álvarez A; Magaña-Aquino M; Romano-Moreno S
    Antimicrob Agents Chemother; 2020 Apr; 64(5):. PubMed ID: 32041715
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.